Washington: Artificial pancreas may soon become a reality, thanks to the advances in continuous glucose monitoring technology.
Researchers from Mary ann liebert, inc./genetic engineering news found that as the accuracy, reliability, adoption, and successful use of Continuous Glucose Monitoring (CGM) continue to increase, the ultimate goal of combining CGM with an insulin pump and sophisticated algorithms for automating the control and suspension of insulin infusion, known as the artificial pancreas tend to move closer to becoming a reality.
Researchers Jort Kropff and J. Hans DeVries from University of Amsterdam (The Netherlands) have explored how CGM technology has affected diabetes treatment and clinical outcomes.
Additionally, David Rodbard has examined the barriers to clinical implementation of CGM systems that have limited their use despite tremendous improvements in recent years.
DTT Editor-in-Chief Satish Garg from the University of Colorado Denver said with different approaches to an artificial pancreas currently in development and ongoing advances in predictive algorithms for automated control, he is hopeful that some version of a closed-loop system will be available in the U.S. within the next two years.
The study is published in the journal Diabetes Technology & Therapeutic.